Steven E Schumacher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5659511/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Analyses of non-coding somatic drivers in 2,658Âcancer whole genomes. Nature, 2020, 578, 102-111.	27.8	424
2	Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nature Genetics, 2020, 52, 331-341.	21.4	431
3	Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18.	28.9	1,670
4	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 2018, 173, 291-304.e6.	28.9	1,718
5	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	28.9	2,111
6	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
7	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	14.3	3,706
8	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Reports, 2018, 23, 172-180.e3.	6.4	119
9	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Reports, 2018, 23, 213-226.e3.	6.4	83
10	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 2018, 23, 239-254.e6.	6.4	801
11	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Reports, 2018, 23, 255-269.e4.	6.4	204
12	The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell, 2018, 33, 244-258.e10.	16.8	270
13	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 2018, 6, 282-300.e2.	6.2	284
14	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.	16.8	750
15	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	16.8	396
16	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	16.8	478
17	SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Research, 2018, 28, 581-591.	5.5	288
18	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-12 Superfamily. Cell Systems, 2018, 7, 422-437.e7.	6.2	134

#	Article	IF	CITATIONS
19	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Reports, 2018, 25, 1304-1317.e5.	6.4	329
20	Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nature Medicine, 2018, 24, 968-977.	30.7	196
21	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro-Oncology, 2017, 19, now294.	1.2	54
22	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	16.8	532
23	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 2017, 169, 1327-1341.e23.	28.9	1,794
24	Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers. Gastroenterology, 2017, 153, 536-549.e26.	1.3	90
25	Genomic landscape of high-grade meningiomas. Npj Genomic Medicine, 2017, 2, .	3.8	130
26	Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell, 2017, 31, 411-423.	16.8	309
27	Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. Neoplasia, 2017, 19, 75-83.	5.3	27
28	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	27.8	787
29	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell, 2017, 32, 204-220.e15.	16.8	642
30	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2017, 32, 185-203.e13.	16.8	1,428
31	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell, 2017, 171, 950-965.e28.	28.9	738
32	Landscape of Genomic Alterations in Pituitary Adenomas. Clinical Cancer Research, 2017, 23, 1841-1851.	7.0	94
33	Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nature Genetics, 2017, 49, 10-16.	21.4	307
34	Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. PLoS ONE, 2017, 12, e0176045.	2.5	28
35	Genomic evolution and chemoresistance in germ-cell tumours. Nature, 2016, 540, 114-118.	27.8	139
36	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	16.8	482

STEVEN E SCHUMACHER

#	Article	IF	CITATIONS
37	Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Scientific Reports, 2016, 6, 25521.	3.3	13
38	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	21.4	214
39	<i>MECP2</i> Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy. Cancer Discovery, 2016, 6, 45-58.	9.4	57
40	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro-Oncology, 2015, 17, 1486-1496.	1.2	39
41	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-Oncology, 2015, 17, 1344-1355.	1.2	40
42	Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background. Genome Research, 2015, 25, 1634-1645.	5.5	96
43	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. Cancer Cell, 2014, 25, 91-101.	16.8	847
44	Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nature Genetics, 2014, 46, 588-594.	21.4	144
45	BET Bromodomain Inhibition of <i>MYC</i> -Amplified Medulloblastoma. Clinical Cancer Research, 2014, 20, 912-925.	7.0	296
46	Pan-cancer patterns of somatic copy number alteration. Nature Genetics, 2013, 45, 1134-1140.	21.4	1,616
47	Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nature Genetics, 2013, 45, 478-486.	21.4	671
48	Systematic Interrogation of 3q26 Identifies <i>TLOC1</i> and <i>SKIL</i> as Cancer Drivers. Cancer Discovery, 2013, 3, 1044-1057.	9.4	71
49	ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Research, 2013, 23, 665-678.	5.5	110
50	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor <i>MYBL1</i> . Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8188-8193.	7.1	188
51	Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers. PLoS ONE, 2013, 8, e54873.	2.5	70
52	Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis. Cancer Research, 2012, 72, 4383-4393.	0.9	242
53	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	27.8	761
54	β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis. Cell, 2012, 151, 1457-1473.	28.9	647

#	Article	IF	CITATIONS
55	Cancer Vulnerabilities Unveiled by Genomic Loss. Cell, 2012, 150, 842-854.	28.9	209
56	Sequence analysis of mutations and translocations across breast cancer subtypes. Nature, 2012, 486, 405-409.	27.8	1,107
57	GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biology, 2011, 12, R41.	8.8	2,546
58	Genetic and Functional Studies Implicate <i>HIF1</i> α as a 14q Kidney Cancer Suppressor Gene. Cancer Discovery, 2011, 1, 222-235.	9.4	347